VerticalVet and Zomedica Entered a Collaborative Era Announcement Zomedica Corp., a veterinary health company providing therapeutic solutions and advanced diagnostics for equine and companion animals, has entered a partnership with Verticalvet, a reputable veterinary industry group purchasing or...
Opus Genetics Received FDA Approval for the IND Application Announcement Opus Genetics leading clinical-stage biopharmaceutical company initiating gene therapies for inherited retinal disease (IRD) treatment and small molecule therapies for different ophthalmic disorders, received FDA clearanc...
IQVIA and Veeva’s Global Commercial and Clinical Partnership and Clearance of Legal Disputes Announcement Veeva Systems and IQVIA entered a long-term commercial and clinical partnership and have completed settlement of all remaining legal issues. In this global agreement, the customers c...
Pharmacyte Biotech Signed a Securities Purchase Agreement with Existing Investors Announcement Pharmacyte Biotech Inc. has signed a securities purchase agreement worth $7.0 million under financial terms with existing investors, engaging the sale of 7,000 shares of its newly positioned Se...
Subordinate of Dx&Vx Avixgen Entered a Licensing-out Agreement with a US Biotech Company Announcement Avixgen, a secondary of Dx&Vx, declared on 18th August 2025 that it has entered a licensing out agreement at USD 360 million with a US biotechnology company to introduce a next-g...
Caris Life Sciences Proves its FDA-approved MI Cancer Seek® Announcement Caris Life Sciences, a global patient-oriented, promising AI techbio company, released a study in Oncotarget validating the clinical and analytical potential of MI Cancer Seek. This regulatory-approved assay is consi...
SpinaFX’s Device Received Approval as a Groundbreaking Device Designation by the US FDA Announcement The spinaFX Medical Inc., a known innovator in image-guided interventional spine care, has been positioned as a groundbreaking device designation for its main device, Triojection, by the ...
Ascentage’s Phase 3 Study of Lisaftoclax Announcement Ascentage Pharma, a leading marketizing level merger biopharmaceutical company involved in the development, exploration, and marketing of numerous different therapies to identify required medical needs in cancer, has received approval...
Valneva’s Chikungunya Vaccine Received Authorization in Canada Announcement Valneva SE, a specialized vaccine company, received marketing authorization from Health Canada for the single-dose vaccine IXCHIQ for serving prevention of disease related to the chikungunya virus for individual...
CIT and IFLI Partnered to Advance Cancer Therapies Announcement CIT Therapeutics Inc., a leading biotechnology company primarily aimed at accelerating next-generation small molecule therapeutics focusing on sumoylation for cancer treatment, has entered a partnership deal with the Institute for...
